Antibody testing for autoimmune neurological disorders: Which tests to order and why
Kumar, P., Mousavi, A., and Frykman, H. (2022). Antibody testing for autoimmune neurological disorders: Which tests to order and why? Academy of Diagnostics & Laboratory Medicine – Scientific Short. Available from: https://myadlm.org/science-and-research/scientific-shorts/2022/antibody-testing-for-autoimmune-neurological-disorders-which-tests-to-order-and-why
Utility of Live Cell-Based Assay for Autoimmune Neurology Diagnostic
Woodhall, M., Mgbachi, V., Fox, H., Irani, S., & Waters, P. (2022). Utility of live cell-based assays for autoimmune neurology diagnostics. The Journal of Applied Laboratory Medicine, 7(1), 391–393. https://doi.org/10.1093/jalm/jfab133
p-tau217
Analytical considerations and clinical utility of plasma phosphorylated Tau217
Frykman H. Analytical considerations and clinical utility of plasma phosphorylated Tau217. Critical Reviews in Clinical Laboratory Sciences. 2026;63(2):124-134.
Cracking the Alzheimer’s code-Emerging blood biomarkers for clinical diagnosis
Kumar, P., Mousavi, A., and Frykman, H. (2025). Cracking the Alzheimer’s code: Emerging blood biomarkers for clinical diagnosis. Academy of Diagnostics & Laboratory Medicine – Scientific Short. Available from: https://myadlm.org/science-and-research/scientific-shorts/2025/cracking-alzheimers-code.
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: a Canadian prospective
Kumar, P., Mousavi, A., & Frykman, H. (2025). The biological diagnosis of Alzheimer’s disease using blood‑based biomarkers: A Canadian prospective. Clinical Biochemistry, 139, 110980. https://doi.org/10.1016/j.clinbiochem.2025.110980
Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples
Mammel, A.E., Hsiung, G.Y.R., Mousavi, A., et al. (2025). Clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples. Alzheimer’s & Dementia. 17(1):e70070. https://doi.org/10.1002/dad2.70070
Myasthenia Gravis
The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments
Mousavi A, Kumar P, Frykman H. The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments. Clinical Biochemistry. 2024;133-134:110826.
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis
Damato V, Spagni G, Monte G, et al. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(9):995-1000.
Laboratory Testing of Myasthenia Gravis- New Treatments Drive Change
Frykman H, Kumar P. Laboratory testing of myasthenia gravis: new treatments drive change. The Journal of Applied Laboratory Medicine. 2021;6(4):1087-1089.
Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies
Frykman H, Kumar P, Oger J. Immunopathology of autoimmune myasthenia gravis: implications for improved testing algorithms and treatment strategies. Front Neurol. 2020;11:596621.
MOGAD and NMO
Real World Clinical Experience with Serum MOG and AQP4 Antibody Testing by Live versus Fixed Cell‐Based Assay
Said, Y., Filippatou, A., Tran, C., Rezavi, L., Guo, K., Smith, M. D., … Sotirchos, E. S. (2025). Real‐world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell‐based assay. Annals of Clinical and Translational Neurology, 12(3), 556–564. https://doi.org/10.1002/acn3.52310
Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid
Redenbaugh, V., Fryer, J. P., Cacciaguerra, L., Chen, J. J., Greenwood, T. M., Gilligan, M., … Flanagan, E. P. (2024). Diagnostic utility of MOG antibody testing in cerebrospinal fluid. Annals of Neurology, 96(1), 34–45. https://doi.org/10.1002/ana.26931
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria
Supplementary appendix to Banwell et al. (2023), BCNI Lab included
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., … Palace, J. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. The Lancet Neurology, 22(3), 268–282. https://doi.org/10.1016/S1474-4422(22)00431-8
Autoimmune Encephalitis and Paraneoplastic Antibody Syndrome
Paraneoplastic LCBA vs FCBA
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I): Antibodies to Intracellular Antigens
Milano, C., Businaro, P., Papi, C., Arlettaz, L., Marmolejo, L., Naranjo, L., … Spatola, M. (2025). Assessing commercial tissue-based assays for autoimmune neurologic disorders (I): Antibodies to intracellular antigens. Neurology Neuroimmunology & Neuroinflammation, 12(4), e200410. https://doi.org/10.1212/NXI.0000000000200410
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II): Antibodies to Surface Antigens
Papi, C., Milano, C., Arlettaz, L., Businaro, P., Marmolejo, L., Naranjo, L., … Spatola, M. (2025). Assessing commercial tissue-based assays for autoimmune neurologic disorders (Ii): Antibodies to surface antigens. Neurology Neuroimmunology & Neuroinflammation, 12(4), e200406. https://doi.org/10.1212/NXI.0000000000200406
An Opinion on the Clinical Laboratory Testing following the New 2021 PNS-Care Diagnostic Criteria
Frykman, H., & Kumar, P. (2022). An opinion on the clinical laboratory testing following the new 2021 pns-care diagnostic criteria. The Journal of Applied Laboratory Medicine, 7(1), 367–372. https://doi.org/10.1093/jalm/jfab154
Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis
Ruiz-García, R., Muñoz-Sánchez, G., Naranjo, L., Guasp, M., Sabater, L., Saiz, A., … Martinez-Hernandez, E. (2021). Limitations of a commercial assay as diagnostic test of autoimmune encephalitis. Frontiers in Immunology, 12, 691536. https://doi.org/10.3389/fimmu.2021.691536